Medgenics Reports Open Market Purchase of Common Stock by Director
December 18 2013 - 8:30AM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the
Company), the developer of Biopump(TM) a novel technology for the
sustained production and delivery of therapeutic proteins in
patients using their own tissue, announces that the Company was
informed today by Dr. Alastair Clemow, a director of the Company
that he purchased 4,500 shares of common stock on the open market
on December 16, 2013 at an average price of $5.7787 per share.
Following this purchase, Dr. Clemow now owns 18,500 shares of
common stock, which represents approximately 0.1 per cent of the
total issued shares of common stock. Dr. Clemow also has the right
to purchase up to 105,714 shares of common stock pursuant to
options previously granted (in aggregate Dr. Clemow’s shares of
common stock and options represent 124,214 shares of common stock
which represent approximately 0.7 per cent of the Company’s total
issued shares of common stock).
This announcement is being made pursuant to the London Stock
Exchange’s AIM Rules for Companies admitted to trading on the AIM
market.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Medgenics, Inc.John Leaman,
CFOjohn.leaman@medgenics.comorLHAAnne Marie
Fields212-838-3777afields@lhai.com@LHA_IR_PRorAbchurch
CommunicationsJoanne Shears / Jamie Hooper / Harriet Rae+44 207 398
7718harriet.rae@abchurch-group.comorOriel Securities (NOMAD &
Broker)Jonathan Senior / Giles Balleny+44 207 710 7617
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Sep 2023 to Sep 2024